Review: Nanocarrier Systems Could Solve Liraglutide's Delivery Challenges
Novel nanocarrier-based delivery systems show promise in overcoming liraglutide's poor oral bioavailability and stability limitations, potentially enabling more effective and convenient treatment.
Quick Facts
What This Study Found
Multiple nanocarrier platforms (polymeric, lipid-based, and hybrid systems) have demonstrated improved liraglutide stability, protection from degradation, and enhanced bioavailability in preclinical studies.
Key Numbers
- No specific efficacy numbers reported
- Six nanocarrier platforms reviewed: nanofibers, liposomes, polymeric NPs, exosomes, hydrogels, lipid NPs
How They Did This
Narrative review surveying the scientific literature on liraglutide pharmacology, delivery challenges, and novel nanocarrier-based systems including their mechanisms, advantages, and preclinical performance.
Why This Research Matters
Liraglutide requires daily injections, which limits patient compliance and quality of life. Nanocarrier technologies could enable oral delivery or less frequent dosing, making this important medication more accessible and convenient for millions of patients.
The Bigger Picture
The delivery challenges facing liraglutide are shared by virtually all peptide therapeutics. Advances in nanocarrier technology for liraglutide could be adapted for other GLP-1 drugs, insulin, and the growing number of peptide-based medications entering the market.
What This Study Doesn't Tell Us
Review article — synthesizes existing literature but generates no new data; most nanocarrier studies are preclinical with limited human data; manufacturing scalability and cost remain significant barriers; regulatory pathway for nano-formulated peptides is complex.
Questions This Raises
- ?Which nanocarrier platform is closest to clinical translation for liraglutide oral delivery?
- ?How do nanocarrier-delivered peptides compare in cost to current injectable formulations?
- ?Could nanocarrier approaches eliminate the need for refrigerated storage of peptide drugs?
Trust & Context
- Key Stat:
- Multiple nanocarrier platforms Polymeric, lipid, and hybrid systems all show improved liraglutide delivery in preclinical testing
- Evidence Grade:
- Narrative review providing a comprehensive overview of the field. Useful for understanding the landscape but not a systematic evidence synthesis.
- Study Age:
- Published in 2025, capturing the latest advances in peptide nanocarrier delivery technology.
- Original Title:
- A comprehensive review on liraglutide and novel nanocarrier-based systems for the effective delivery of liraglutide.
- Published In:
- Naunyn-Schmiedeberg's archives of pharmacology, 398(7), 8241-8258 (2025)
- Authors:
- Pandey, Ajay, Rath, Goutam, Chawala, Ruchi, Goyal, Amit Kumar
- Database ID:
- RPEP-12933
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
Why can't you just swallow a liraglutide pill?
Liraglutide is a peptide — a small protein — that would be rapidly destroyed by stomach acid and digestive enzymes. Nanocarriers are tiny protective shells that can shield the peptide as it passes through the stomach and help it get absorbed into the bloodstream.
What types of nanocarriers are being developed for peptide drugs?
Several types are being explored: polymeric nanoparticles (tiny plastic-like spheres), lipid nanoparticles (fat-based carriers similar to those used in mRNA vaccines), and hybrid systems that combine different materials for optimal protection and delivery.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12933APA
Pandey, Ajay; Rath, Goutam; Chawala, Ruchi; Goyal, Amit Kumar. (2025). A comprehensive review on liraglutide and novel nanocarrier-based systems for the effective delivery of liraglutide.. Naunyn-Schmiedeberg's archives of pharmacology, 398(7), 8241-8258. https://doi.org/10.1007/s00210-025-03918-1
MLA
Pandey, Ajay, et al. "A comprehensive review on liraglutide and novel nanocarrier-based systems for the effective delivery of liraglutide.." Naunyn-Schmiedeberg's archives of pharmacology, 2025. https://doi.org/10.1007/s00210-025-03918-1
RethinkPeptides
RethinkPeptides Research Database. "A comprehensive review on liraglutide and novel nanocarrier-..." RPEP-12933. Retrieved from https://rethinkpeptides.com/research/pandey-2025-a-comprehensive-review-on
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.